Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019; 21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Workplace wellness programs contribute to the wellness movement by enlisting nontraditional health partners and influencing social determinants of health.
AMA J Ethics. 2016; 18(4):393-398. doi:
10.1001/journalofethics.2016.18.4.nlit1-1604.
Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?”